Meeting
2011 ASCO Annual Meeting
Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.
Authors
A. K. Sears
Brooke Army Medical Center, San Antonio, TX
A. K. Sears , G. T. Clifton , R. Patil , N. M. Shumway , M. G. Carmichael , D. C. Van Echo , J. P. Holmes , S. Ponniah , E. A. Mittendorf , G. E. Peoples
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00854789, NCT00841399, NCT0524277
Citation
J Clin Oncol 29: 2011 (suppl; abstr 564)
Abstract #
564
Poster Bd #
4F
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace
Poster
2013 ASCO Annual Meeting
Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.
First Author: Ritesh Patil
Poster
2022 ASCO Annual Meeting
A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.
First Author: Snehal Patel
First Author: Snehal Patel